Hyderabad- People suffering from arthritis should maintain an active lifestyle as physical exercise reduces inflammation by reducing fat and increasing the production and release of anti-inflammatory molecules, say doctors on World Arthritis Day.
Each year, October 12 is commemorated as World Arthritis Day, and this year, doctors recommend people to take a pledge to enhance awareness about arthritis, its related problems, to stay fit and active, and strive towards reducing the overall arthritis case burden in the country.
Arthritis is an autoimmune condition or a degenerative joint disorder, both causing inflammation in the joints, and these are chronic-cum debilitating problems. At present, there is no specified cure for this ailment, except to live with the problem and manage it from time to time, using steroids. Arthritis can cause severe pain, reduces the quality of life, and decrease people's ability to function.
Doctors warn that more Indians could become victims of arthritis-linked problems due to overweight and obesity. The prevalence of overweight and obesity in India is increasing faster than the world average.
The prevalence of overweight increased from 8.4 percent to 15.5 percent among women between 1998 and 2020, and the prevalence of obesity increased from 2.2 percent to 5.1 percent over the same period. Men are not behind in this problem, and together they are adding to the rising burden of arthritis cases in the country.
"Overweight or obesity along with problems like diabetes, suffering from a traumatic injury to joints, congenital joint deformities, could lead to arthritis problems. While there is a slight difference in osteoarthritis and rheumatoid arthritis, both cause severe damage to human functions. And people who are obese are likely to suffer more than lighter peers after they cross a certain age threshold," said Jagan Mohan Reddy, Consultant Orthopedic Surgeon, SLG Hospitals.
According to K. Saketh, Consultant Orthopedic Surgeon (Sports Surgery & Regenerative Orthopedics), Gleneagles Global Hospital, severe pain in the joints deter arthritis patients from taking up any physical activity due to fear that it could worsen their condition.
"But it is important that individuals suffering from arthritis maintain an active lifestyle. Otherwise, a sedentary lifestyle will further debilitate their ability to do any physical activity, and this could have a severe psychological bearing on the mind. Hence, it is important arthritis patients do not stay immobile and instead motivate themselves to walk or exercise regularly."
Satyanarayana V V, Consultant Orthopedic Surgeon, Aware Gleneagles Global Hospital, pointed out that physical exercise reduces inflammation by reducing fat and increasing the production and release of anti-inflammatory molecules from human muscles.
"Given that inflammation is a primary cause of joint pain in arthritis, exercising will help improve symptoms and will play a crucial role in managing the problem," he said.
Read More► Myth or Fact: Exercise Must Be Avoided After A Heart Attack
New York, Aug 7 (IANS) In a bid to help doctors treat pancreatic cancer in a better way, a team of MIT researchers has developed an immunotherapy strategy.The study, published in the journalACancer Cell, indicates that the immunotherapy strategy has shown that it can eliminate pancreatic tumors in mice.The new therapy, which is a combination of three drugs that help boost the body's immune defences against tumors, is likely to enter clinical trials later this year."We don't have a lot of good options for treating pancreatic cancer. It's a devastating disease clinically," said researcher William Freed-Pastor from the Massachusetts Institute of Technology in the US.According to the researchers, pancreatic cancer, which affects about 60,000 Americans every year, is one of the deadliest forms of cancer. After diagnosis, fewer than 10 percent of patients survive for five years.The researchers said that the body's immune system contains T cells that can recognise and destroy cells that express cancerous proteins, but most tumors create a highly immunosuppressive environment that disables these T cells, helping the tumour to survive.Immune checkpoint therapy -- the most common form of immunotherapy currently being used clinically -- works by removing the brakes on these T cells, rejuvenating them so they can destroy tumours.One class of immunotherapy drug that has shown success in treating many types of cancer targets the interactions between PD-L1, a cancer-linked protein that turns off T cells, and PD-1, the T cell protein that PD-L1 binds to.Drugs that block PD-L1 or PD-1, also called checkpoint inhibitors, have been approved to treat cancers such as melanoma and lung cancer, but they have very little effect on pancreatic tumours.Alongside the clinical trial, the MIT team plans to analyse which types of pancreatic tumours might respond best to this drug combination.--IANSvc/in
New York, July 31 (IANS) A team of researchers has leveraged two new molecules, one of which is currently in clinical oncology trials, to devise a dual-drug therapy for alcohol use disorder (AUD), without the side-effects or complications associated with current treatment regimens.The study, published in the journal Nature Communications, indicates that the approach had highly successful results in mice and may apply to other drugs that are often abused."Alcohol use disorder is really a process of maladapted learning and memory," said researcher Dorit Ron from the University of California, San Francisco."Alcohol is rewarding, and we learn to associate alcohol, and even the environment in which we drink the alcohol, with that reward," Ron added.At the root of the team's thinking is the idea that AUD and other substance abuse disorders are the results of reinforced pathways in the brain, and that those pathways can be blocked or redirected, ending cravings and habitual behaviour.The researcher said she is studying the role of the enzyme mTORC1 in the creation of those memories and associations, to create an effective drug that can treat the neurological causes of AUD.Ordinarily, mTORC1 is involved in brain plasticity, helping to create connections between neurons that reinforce memory. In previous work, Ron showed that consuming alcohol activates the enzyme in the brain.Ron has also shown that blocking the activity of mTORC1 with the FDA-approved compound rapamycin, used to treat some types of cancer and suppress the immune response in transplant patients, can halt cravings in mice engineered for alcohol use disorder.But mTORC1 contributes to a bevy of other bodily tasks related to metabolism and liver function, and people taking it for an extended period often develop liver toxicity, glucose intolerance, and other side effects.Ron believes that tackling addiction from a neurological perspective has potential for broad applications."We could see these side effects in mice who are taking rapamycin or RapaLink-1, and then when you give Rapablock, it's like magic, the side effects are gone," Ron noted.--IANSvc/arm
Thiruvananthapuram, July 13 (IANS) Ayurveda experts have suggested that modern healthcare and the traditional system can complement each other to effectively control the pandemic and protect more lives.Addressing a virtual conference organised by the Kerala-headquartered Vaidyaratnam Group, experts of the ancient healthcare system said that by blending classical theory and practice with modern science, ayurveda has managed to effectively treat mild to moderate cases of Covid in the country."Synergy between tradition supported by technology is the new normal that we have to take forward. We need to retain and revive this traditional knowledge on the basis of scientific rigor," said Tanuja Nesari, director, All India Institute of Ayurveda (AIIA), New Delhi.The virtual ceremony was organised as part of founder's commemoration day of the Vaidyaratnam Group.Addressing the second and concluding day of the conference, Nesari noted that a significant 99.99 per cent of the patients who were treated for Covid had recovered well at AIIA's Covid care centre.Sharing her experience of treating Covid patients, with ayurveda practitioners from across India, she said that each and every patient was supported by yoga, diet, lifestyle, recreation and the treatment was also aided by technology."We have retained the classical crux, the principle theory and practices of ayurveda, developed our own holistic treatment protocol and it's all supported by conventional bio-medical tools of investigation like MRI, CT Scan, ventilators, RT-PCR test, oxygen therapists."According to the director of Vaidyaratnam Group, E.T. Neelakandhan Mooss, the judicious use of advancements in other streams of science has helped validating ayurveda in the global platform, where the tag of "traditional medicine" got replaced with "evidence based medicine".Describing Vaidyaratnam Ayurveda Research Institute (VARI) as one such place where expert scientists integrate ayurveda with the latest technology, he said that the advancement in the field of ayurvedic raw drug agriculture using 'Miyawaki' method to the identification of new drug delivery systems are backed up by the latest trends of science and technology."Thus, the Vaidyaratnam Group has always been trying to scientifically update its different verticals like cultivation, medicine manufacturing, process validation, drug discovery and healthcare without losing its quality," he said.With children likely to be more susceptible to Covid infection during the anticipated third wave amidst a slow pace of vaccination in many parts of the country, the two day conference held to formulate a uniform ayurveda treatment protocol for children also underlined the need for preventive measures.Experts emphasised the need for proper diet, healthy lifestyle, recreation and yoga, along with Covid appropriate behaviour like maintaining safe distance and sanitation would keep children safe amid the pandemic.--IANSsg/skp/bg
London, July 7 (IANS) Arthritis drugs tocilizumab and sarilumab can reduce the risk of death and the need for mechanical ventilation in patients with Covid-19, finds a study.The results, based on analysis of 27 randomised trials in 28 countries involving nearly 11,000 patients, have also prompted the World Health Organisation (WHO) to recommend its use in patients with severe or critical Covid-19 along with corticosteroids.The study, published in the Journal of the American Medical Association (JAMA), showed that administering one of these drugs in addition to corticosteroids, in hospitalised patients, reduces the risk of death by 17 per cent, compared to the use of corticosteroids alone.In patients not on mechanical ventilation, the risk of mechanical ventilation or death is reduced by 21 per cent, compared to the use of corticosteroids alone.These are the first drugs found to be effective against Covid-19 since corticosteroids were recommended by WHO in September 2020.Patients severely or critically ill with Covid-19 often suffer from an overreaction of the immune system, which can be very harmful to the patient's health. Interleukin-6 blocking drugs -- tocilizumab and sarilumab -- act to suppress this overreaction."These drugs offer hope for patients and families who are suffering from the devastating impact of severe and critical Covid-19. But IL-6 receptor blockers remain inaccessible and unaffordable for the majority of the world," WHO Director General Dr Tedros Adhanom Ghebreyesus said in a statement."The inequitable distribution of vaccines means that people in low- and middle-income countries are most susceptible to severe forms of Covid-19. So, the greatest need for these drugs is in countries that currently have the least access. We must urgently change this."To increase access and affordability of these life-saving products, the WHO called on manufacturers to reduce prices and make supplies available to low- and middle-income countries, especially where Covid-19 is surging.--IANSrvt/vd
Washington, June 26 (IANS) The US Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the drug Actemra (tocilizumab) -- used for arthritis -- for the treatment of hospitalised patients with Covid-19.Under the EUA, the drug can be administered only ot hospitalised adults and pediatric patients (2 years of age and older), receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).However, Actemra is not authorised for use in outpatients with Covid-19, the FDA said in a statement.Clinical trials showed that administering Actemra to hospitalised Covid-19, in addition to routine care which included corticosteroid therapy, reduced the risk of death as well as decreased the amount of time patients remained hospitalised.The risk of patients being placed on ventilators or death was also decreased."Although vaccines have been successful in decreasing the number of patients with Covid-19 who require hospitalisation, providing additional therapies for those who do become hospitalised is an important step in combating this pandemic," said Patrizia Cavazzoni, MD, Director of the FDA's Center for Drug Evaluation and Research.Actemra is a monoclonal antibody that reduces inflammation and is given by intravenous infusion that is FDA-approved for multiple inflammatory diseases, including rheumatoid arthritis.In the case of Covid-19 infection, the immune system can become hyperactive, which may result in worsening of disease. But, Actemra does not directly target SARS-COV-2.Based on the FDA's review of the totality of the scientific evidence available, the agency has determined that it is reasonable to believe that Actemra may be effective in treating Covid-19 for the authorised population.The data supporting this EUA for Actemra are based on four clinical trials. All four clinical trials contribute to the FDA's understanding of Actemra for the treatment of Covid-19.Common side effects of Actemra observed in the Covid-19 trials include constipation, anxiety, diarrhoea, insomnia, hypertension and nausea. The EUA was issued to American biotechnology Genentech, a subsidiary of Swiss multinational healthcare Roche, FDA said.--IANSrvt/in